This also reduces the number of finger pricks and insulin injections. Dr Sweta Budyal, consultant endocrinologist and ...

WASHINGTON (Reuters) - Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a major accomplishment of the Biden administration ...

In our October research highlights, we look at a world-first stem cell transplant which helped a person with type 1 diabetes produce insulin, and how electrical ... Our researchers have harnessed ...

Insulin pumps dose insulin throughout the day to ... Ultimately, I would like to see manufacturers create a true "artificial pancreas" -- pumps that take away all user interaction and can keep ...

Dr Reith was honoured for her role in developing the world’s first insulin pen, a device that has revolutionised the way people with diabetes manage their condition. Her pioneering work transformed ...

COVID-19 can trigger the development of type 2 diabetes because the virus can cause cells in the pancreas to not produce enough insulin by disrupting an individual’s metabolism. Type 2 diabetes is ...

For more information, search 'AI Collaboration Centre QUB'. In the last decade the advances in Artificial Intelligence have made it at the forefront of technology, with many advances improving our ...

Both are related to the body’s ability to synthesise and react to insulin, the hormone that breaks down sugar in the blood to produce energy. Type 1 diabetes, which often starts in childhood, occurs ...

The U.S. Food and Drug Administration on Thursday announced a Class 1 recall for Medtronic MiniMed 600- and 700-series insulin pumps because of an increased risk of shorter battery life that could ...

WARSAW — Medtronic is notifying users of MiniMed 600 and 700 series insulin pumps of an increased risk for reduced battery life and less time until shutdown after a battery alert occurs. Pumps that ...

Opens in a new tab or window A shorter-than-expected battery life prompted a voluntary recall of certain insulin pumps from Medtronic's MiniMed 600 and 700 series, the FDA detailed on Thursday.

A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...